DK167906B1 - Anvendelse af praeparater til brug ved tomo-densitometri - Google Patents
Anvendelse af praeparater til brug ved tomo-densitometri Download PDFInfo
- Publication number
- DK167906B1 DK167906B1 DK637787A DK637787A DK167906B1 DK 167906 B1 DK167906 B1 DK 167906B1 DK 637787 A DK637787 A DK 637787A DK 637787 A DK637787 A DK 637787A DK 167906 B1 DK167906 B1 DK 167906B1
- Authority
- DK
- Denmark
- Prior art keywords
- metal
- derivative
- use according
- tomo
- densitometry
- Prior art date
Links
- 238000000326 densiometry Methods 0.000 title abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229910052751 metal Inorganic materials 0.000 claims abstract description 18
- 239000002184 metal Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- -1 lactobionates Chemical group 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 230000004899 motility Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- UCGJZJXOPSNTGZ-UHFFFAOYSA-M Prifinium bromide Chemical compound [Br-].CC1[N+](CC)(CC)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 UCGJZJXOPSNTGZ-UHFFFAOYSA-M 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 125000005612 glucoheptonate group Chemical group 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 229960005275 prifinium bromide Drugs 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 239000004227 calcium gluconate Substances 0.000 description 4
- 229960004494 calcium gluconate Drugs 0.000 description 4
- 235000013927 calcium gluconate Nutrition 0.000 description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000002970 Calcium lactobionate Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 235000019307 calcium lactobionate Nutrition 0.000 description 3
- 229940050954 calcium lactobionate Drugs 0.000 description 3
- RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 2
- 239000008373 coffee flavor Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 239000001755 magnesium gluconate Substances 0.000 description 2
- 235000015778 magnesium gluconate Nutrition 0.000 description 2
- 229960003035 magnesium gluconate Drugs 0.000 description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- ZYEPZINLLPPBMI-UHFFFAOYSA-N 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium Chemical class CC1[N+](CC)(CC)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 ZYEPZINLLPPBMI-UHFFFAOYSA-N 0.000 description 1
- NGIFHAUKQGDVSR-UHFFFAOYSA-N 6,7-dimethoxy-1-(3,4,5-triethoxyphenyl)isoquinoline Chemical compound CCOC1=C(OCC)C(OCC)=CC(C=2C3=CC(OC)=C(OC)C=C3C=CN=2)=C1 NGIFHAUKQGDVSR-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- JRRNZNSGDSFFIR-UHFFFAOYSA-M Mepenzolate bromide Chemical compound [Br-].C1[N+](C)(C)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 JRRNZNSGDSFFIR-UHFFFAOYSA-M 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229960002562 calcium glucoheptonate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004944 difemerine Drugs 0.000 description 1
- WJIZVQNUJVMJAZ-UHFFFAOYSA-N difemerine Chemical class C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)CN(C)C)C1=CC=CC=C1 WJIZVQNUJVMJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 229940097364 magnesium acetate tetrahydrate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- XKPKPGCRSHFTKM-UHFFFAOYSA-L magnesium;diacetate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].CC([O-])=O.CC([O-])=O XKPKPGCRSHFTKM-UHFFFAOYSA-L 0.000 description 1
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940071125 manganese acetate Drugs 0.000 description 1
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 229960003092 mepenzolate Drugs 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical class C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229950003545 octaverine Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229960002088 pinaverium bromide Drugs 0.000 description 1
- 229960001647 prifinium Drugs 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical class C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Printed Wiring (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Description
i DK 167906 B1
Opfindelsen angår en hidtil ukendt anvendelse af præparater til brug ved tomo-densitometri som anført i krav 1.
Tomo-densitometriteknikken er en metode til undersøgelse og afbildning af det menneskelige legeme, hvorved man 5 bl*a. bliver i stand til at gengive massive organer.
Undersøgelsen af underlivet ved tomo-densitometri nødvendiggør anvendelsen af kontraststoffer til identifikation af de anatomiske elementer.
Takket være endo-venøs indsprøjtning af vandopløselige 10 ioderede forbindelser (betegnet Angio-scan) er man således i stand til at gengive karrene, ligesom parenchymet af massive organer (lever, nyrer, milt).
Hule organer identificeres dog trods anvendelsen af ioderede forbindelser i stærkt fortyndet tilstand ad oral 15 vej. Deres optiske tæthed på den ene side og deres mangel på homogenitet på den anden side gør, at de ikke opfylder forventningerne til anatomisk identifikation og diagnose for patologiske elementer.
Anvendelsen af de hidtil ukendte kontrastpræparater 20 på basis af sådanne metalsalte som calcium-, magnesiumeller zinksalte afhjælper den tidligere kritik: - de udfylder hele lysningen i fordøjelseskanalen på mindre end end en time uden at efterlade et anatomisk tomrum, 25 - de fremhæver på perfekt måde fordøjelseskanalens væg, - deres optiske tæthed gør, at de ikke kan forveksles med et anatomisk naboelement eller et anatomopato- 1ogisk naboelement, - de kan ligeledes benyttes til påvisning af urinblæren 5° og fødselsvejene.
Præparaterne er opløsninger i vand eller i et med organismen forligeligt vandigt miljø med i det mindste et derivat af et ikke-toksisk metal med atomvægt mellem 24 og 66.
55 · Blandt de metalderivater, som kommer i betragtning, skal her nævnes derivater af magnesium, af calcium, af mangan, af jern, af zink og af cobalt.
2 LMV ID/iJUD D |
De anvendelige salte er vandopløselige salte, som muliggør fremstillingen af opløsninger indeholdende 5-25% metalderivat.
Til dette formål benytter man fortrinsvis et chlorid, 5 et nitrat, et sulfat, et acetat, et gluconat, et lactobio-nat, et glucoheptonat eller et gluconoglucoheptonat af metallet.
Man kan således med fordel benytte en opløsning af mag-nesiumchlorid, af calciumnitrat, af ferrigluconat, af cal-10 ciumlactobionat, af calciumgluconoglucoheptonat, af zinksulfat, af manganacetat eller magnesiumformiat.
Når et metal har flere valenser, afgøres valget af derivat i afhængighed af krtiterierne med hensyn til opløselighed og stabilitet af forbindelsen. Man kan f.eks. uden for-15 skel benytte et ferro- eller ferriderivat eller et mangano-eller manganiderivat.
Det kan ligeledes være fordelagtigt at benytte metalderivaterne i form af opløselige komplekser, f.eks. sådanne af ethylendiaminotetraeddikesyre, af ethylenglycol-bis-(y5 20 -aminoethylether)-Ν,Ν,Ν' ,Ν'-tetraeddikesyre, af ethylendiamin-N,N'-dieddikesyre-N,N'-di-o^-propionsyre eller af ethylen-diamino-Ν,Ν'-dieddikesyre-Ν,Ν'-di-β -propionsyre. Disse komplekser kan især være konstitueret med blandede molekyler, som omfatter to eller fire alkalimetalioner som f.eks. kom-25 plekset af ethylendiamintetraeddikesyre med zink i form af tetranatriumsalt.
Anvendelser af metalkomplekser omfatter den fordel, som ligger i svag smag og fravær af toksitet.
Opløsningerne kan desuden være tilsat fortykkelses-30 midler eller midler til forøgelse af viskositeten, sødemidler samt aromatiseringsstoffer.
Opløsningerne er beregnet til at indgives ad oral vej i form af opløsning, sirup eller mikstur eller ad rek-tal vej i form af lavement eller ad endocavitær vej, f.eks.
35 ved instillation i urinblæren eller i fødselsvejene.
Man benytter fortrinsvis en vandig opløsning på 5, 10 eller 15% af et salt af et metal, hvis atomvægt ligger mellem 24 og 66, og sødet med et syntetisk sødemiddel som DK 167906 B1 3
Aspartam eller et saccharinat såsom natrium-eller calcium-saccharinat.
Man kan ligeledes benytte opløsninger indeholdende en blanding af sådanne metalderivater i respektive andele, 5 som varierer fra 1% til 99%, f.eks. en opløsning af lige dele af et magnesiumsalt og et calciumsalt. Saltene kan være afledt af samme anion eller, bortset fra tilfælde af kemisk uforligelighed, af to forskellige anioner.
Til undersøgelse af organerne, navnlig fordøjelses-10 vejene, kan præparaterne desuden omfatte et lægemiddel, som modificerer motriciteten, navnlig et lægemiddel, som reducerer eller undertrykker tarmperistaltik-ken. I denne sammenhæng levnes trimebutin og dets salte, saltene af N-methylscopolamin, saltene af N-butylhyoscin, 15· saltene af prifinium, saltene af difemerin, saltene af atro-pin, saltene af hyosciamin, saltene af scopolamin, saltene af pentapriperium, mepenzolatbromid, piperidolatchlorhydrat, pinaveriumbromid, mebeverinchlorhydrat, octaverinchlorhydrat og oxyphencycliminchlorhydrat.
20 Det rumfang opløsning, som bør indgives, kan variere fra 50 til 500 ml og fortrinsvis fra 100 til 300 ml i afhængighed af indgiftsmåden.
Opløsningerne tillader altså opnåelsen af undersøgelser af fordøjelseskanalen (den høje del eller 25 den lave del af blæren og af fødselsvejen) ved en særlig fin og særlig kontrastrig tomo-densitometri, som gør det muligt på en særlig god måde at se konturerne af hule organer.
Nedenstående eksempler illustrerer opfindelsen.
30 Eksempel I
Vandig opløsning af calciumgluconat . calciumgluconat 25 g . carboxymethylcellulose 0,25 g . Aspartam 0,05 g 35 . kaffearoma q.s.
. destilleret vand ad 250 ml 4 uk io/auo 8 i
Eksempel II
Vandig opløsning af calciumgluconoglucoheptonat . calciumglucoheptonat 30 g . glycerol 5 g 5 . Aspartam 0,05 g . kaffearoma q.s.
. destilleret vand ad 200 ml
Eksempel III
Vandig opløsning af ferrogluconat 10 ferrogluconat 30 g . hydroxypropylmethylcellulose 0,10 g . natriumsaccharinat 0,15 g . destilleret vand ad 200 ml
• Eksempel IV
15 Vandig opløsning af magnesiumacetat . magnesiumacetattetrahydrat 37 g . glycerol 13 g . natriumsaccharinat 0,15 g . destilleret vand ad 200 ml
20 ' Eksempel V
Vandig opløsning af magnesiumgluconat . magnesiumgluconat (hemimagnesiumsalt) 46 g . methylcellulose 4 g . glycerol 10 g 25 . Aspartam 0,05 g . destilleret vand ad 200 ml
Eksempel VI
Vandig opløsning af calciumlactobionat . calciumlactobionat (hemicalciumsalt) 27,5 g 30 . magnesiumacetat 14 g . destilleret vand ad 200 ml
Eksempel VII
Vandig cobaltopløsning . dinatriumcobaltoethylendiaminotetracemat 65 g 35 . carboxymethylcellulose 2,5 g . glycerol 12 g . destilleret vand ad 250 ml 5 DK 167906 B1
Eksempel VIII
Vandig opløsniq af calciumqluconat . calciumgluconat 25 g . carboxymethylcellulose (natriumsalt) 0,05 g 5 . prifiniumbromid 0,05 g . calciumsaccharinat 0,15 g . destilleret vand ad 200 ml 10 15 20 25 30.
35
Claims (8)
1. Anvendelse af præparater indeholdende i det mindste et i vandigt miljø opløseligt derivat af et metal med en atomvægt mellem 24 og 66 i opløsning i et passende vandigt bærestof med et indhold på 5-25% af metalderivatet 5 til indgift ad oral, rektal eller endocavitær til fremstilling af et diagnostisk middel, som anvendes ved tomo-den-sitometriske undersøgelser.
2. Anvendelse ifølge krav 1, kendetegnet ved, at det i vandigt miljø opløselige derivat er et vand- 10 opløseligt salt.
3. Anvendelse ifølge krav 1-2, kendetegnet ved, at metallet vælges blandt magnesium, calcium, jern, mangan, cobalt og zink.
4. Anvendelse ifølge krav 1-3, kendeteg- 15 net ved, at metalderivatet vælges blandt chlorider, nitrater, sulfater, acetater, gluconater, lactobionater, glucoheptonater og gluconoglucoheptonater.
5. Anvendelse ifølge krav 1-3, kendetegnet ved, at metalderivatet er et kompleks af ethylen- 20 diaminotetraeddikesyre eller af ethylendiaminoeddikesyre-dipropion syre med zink eller cobalt.
6. Anvendelse ifølge krav 1-5, kendetegnet ved, at den desuden omfatter et aktivt middel, som modificerer organernes motricitet.
7. Anvendelse ifølge krav 6, kendetegnet ved, at det aktive middel, som modificerer organernes motricitet, er prifiniumbromid.
8. Anvendelse ifølge krav 1-3, kendetegnet ved, at den aktive bestanddel er en blanding af 30 1-99% af et derivat af et metal med atomvægt mellem 24 og 66 og 99-1% af et derivat af et andet metal med atomvægt mellem 24 og 66. 35
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8600116 | 1986-04-07 | ||
| PCT/FR1986/000116 WO1987006139A1 (fr) | 1986-04-07 | 1986-04-07 | Nouvelles compositions utilisables en tomo-densitometrie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK637787D0 DK637787D0 (da) | 1987-12-04 |
| DK637787A DK637787A (da) | 1987-12-04 |
| DK167906B1 true DK167906B1 (da) | 1994-01-03 |
Family
ID=9330870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK637787A DK167906B1 (da) | 1986-04-07 | 1987-12-04 | Anvendelse af praeparater til brug ved tomo-densitometri |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5219552A (da) |
| EP (1) | EP0262123B1 (da) |
| JP (1) | JPH07100666B2 (da) |
| KR (1) | KR880701111A (da) |
| AT (1) | ATE74279T1 (da) |
| AU (1) | AU605461B2 (da) |
| DE (1) | DE3684711D1 (da) |
| DK (1) | DK167906B1 (da) |
| FI (1) | FI92977C (da) |
| HU (1) | HU200104B (da) |
| NO (1) | NO176202C (da) |
| WO (1) | WO1987006139A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
| US20030185757A1 (en) * | 2002-03-27 | 2003-10-02 | Mayk Kresse | Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542915A (en) * | 1965-10-22 | 1970-11-24 | Laurence G Bodkin | X-ray detection of cancer with water-soluble salts of iron and bismuth |
| US3832457A (en) * | 1969-06-20 | 1974-08-27 | Rikagaku Kenkyusho | Ferrite contrast media with metallic oxides |
| SE7504915L (sv) * | 1974-04-30 | 1975-10-31 | Solco Basel Ag | Medel for att diagnostiskt synliggora neoplastiska vevnader. |
| DE3129906C3 (de) * | 1981-07-24 | 1996-12-19 | Schering Ag | Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik |
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| NL194579C (nl) * | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
| US4423158A (en) * | 1983-01-27 | 1983-12-27 | Gelinnovation Handelsaktiebolag | Ion adsorbent for metals having a coordination number greater than two |
| US4481184A (en) * | 1983-02-14 | 1984-11-06 | E. R. Squibb & Sons, Inc. | Cationic technetium (I) complexes |
| DE3324235A1 (de) * | 1983-07-01 | 1985-01-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue komplexbildner, komplexe und komplexsalze |
| GB8413772D0 (en) * | 1984-05-30 | 1984-07-04 | Nyegaard & Co As | Chemical compounds |
| CA1260827A (en) * | 1984-08-31 | 1989-09-26 | Richard C. Siegel | Antibody-metal ion complexes |
| US4687659A (en) * | 1984-11-13 | 1987-08-18 | Salutar, Inc. | Diamide-DTPA-paramagnetic contrast agents for MR imaging |
| PT81498B (pt) * | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
| US4758422A (en) * | 1985-01-04 | 1988-07-19 | Salutar Inc. | Ferrioxamine paramagnetic contrast agents for MR imaging |
| GB8518300D0 (en) * | 1985-07-19 | 1985-08-29 | Amersham Int Plc | Contrast agent |
| US4735793A (en) * | 1985-08-30 | 1988-04-05 | Massachusetts Institute Of Technology | Carboxy, carboalkoxy and carbamile substituted isonitrile radionuclide complexes |
| WO1987002893A1 (en) * | 1985-11-18 | 1987-05-21 | Board Of Regents, The University Of Texas System | Polychelating agents for image and spectral enhancement (and spectral shift) |
| US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| IT1213029B (it) * | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
-
1986
- 1986-04-07 JP JP61502120A patent/JPH07100666B2/ja not_active Expired - Lifetime
- 1986-04-07 KR KR1019870701152A patent/KR880701111A/ko not_active Ceased
- 1986-04-07 WO PCT/FR1986/000116 patent/WO1987006139A1/fr not_active Ceased
- 1986-04-07 EP EP86902412A patent/EP0262123B1/fr not_active Expired - Lifetime
- 1986-04-07 AT AT86902412T patent/ATE74279T1/de active
- 1986-04-07 US US07/139,250 patent/US5219552A/en not_active Expired - Fee Related
- 1986-04-07 AU AU56908/86A patent/AU605461B2/en not_active Ceased
- 1986-04-07 DE DE8686902412T patent/DE3684711D1/de not_active Expired - Lifetime
- 1986-04-07 HU HU863058A patent/HU200104B/hu not_active IP Right Cessation
-
1987
- 1987-12-04 NO NO875066A patent/NO176202C/no not_active IP Right Cessation
- 1987-12-04 DK DK637787A patent/DK167906B1/da not_active IP Right Cessation
- 1987-12-07 FI FI875379A patent/FI92977C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5219552A (en) | 1993-06-15 |
| JPH07100666B2 (ja) | 1995-11-01 |
| NO176202C (no) | 1995-02-22 |
| FI875379L (fi) | 1987-12-07 |
| KR880701111A (ko) | 1988-07-25 |
| DE3684711D1 (de) | 1992-05-07 |
| NO176202B (no) | 1994-11-14 |
| EP0262123B1 (fr) | 1992-04-01 |
| DK637787D0 (da) | 1987-12-04 |
| NO875066D0 (no) | 1987-12-04 |
| WO1987006139A1 (fr) | 1987-10-22 |
| FI92977C (fi) | 1995-02-10 |
| DK637787A (da) | 1987-12-04 |
| ATE74279T1 (de) | 1992-04-15 |
| FI875379A0 (fi) | 1987-12-07 |
| NO875066L (no) | 1988-01-11 |
| AU5690886A (en) | 1987-11-09 |
| EP0262123A1 (fr) | 1988-04-06 |
| HU200104B (en) | 1990-04-28 |
| JPS63502987A (ja) | 1988-11-02 |
| FI92977B (fi) | 1994-10-31 |
| AU605461B2 (en) | 1991-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100297264A1 (en) | Bowel purgative and uses thereof | |
| TWI535461B (zh) | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 | |
| US9149493B2 (en) | Compositions for bowel cleansing and use thereof | |
| JP2019123729A (ja) | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト | |
| CA2000112C (en) | Iron containing preparation for nmr imaging and nmr imaging method using the same | |
| WO2019092242A1 (en) | A double-labeled probe for molecular imaging and use thereof | |
| ES2409842T3 (es) | Composiciones para la limpieza intestinal y uso de las mismas | |
| CN119490506B (zh) | 靶向叶酸受体的小分子化合物及制备方法、组合物和应用 | |
| CA2747947A1 (en) | Contrast media for use in medical and diagnostic procedures and methods of using the same | |
| RS56574B1 (sr) | Sulfatne soli za popravljanje tranzitnog vremena | |
| JP2005507407A (ja) | 腸管洗浄製剤 | |
| CN103550249B (zh) | 一种用于肠道准备的药物组合物 | |
| JP2004504017A (ja) | 感染症および他の疾患の治療に用いられる、生物活性タンパク質としての新規なヒト・デフェンシンの回収および適用方法 | |
| FI92977B (fi) | Koostumuksia käytettäviksi tomodensitometriassa | |
| JP4731493B2 (ja) | 経口投与用ｍｒｉ造影剤組成 | |
| JP5206616B2 (ja) | Ｃｔコロノグラフィにおける消化管造影用組成物 | |
| JP2021504472A (ja) | 重水素化２−アミノ−２−メチルプロピオン酸および／または２−（ｎ−メチルアミノ）−２−メチルプロピオン酸を含有する腫瘍学的病気の磁気共鳴診断のための調剤薬、およびその調剤薬を使用した診断方法 | |
| JP2005002006A (ja) | Ｃｔコロノグラフィにおける消化管造影用組成物 | |
| JP2909876B2 (ja) | 造影剤 | |
| JP5696326B2 (ja) | Ｃｔコロノグラフィ検査用医薬 | |
| KR20200101079A (ko) | 네크록스-5를 포함하는 폐 섬유증의 예방 또는 치료용 조성물 | |
| LaGrange et al. | The effect of sodium thiosulfate administration on nephrocalcinosis in a rat model | |
| US11207429B2 (en) | Method and compositions for orally administered contrast agents for MR imaging | |
| WO2010099804A1 (en) | Magnetic resonance imaging of the liver | |
| JP5505454B2 (ja) | Ｃｔコロノグラフィにおける消化管造影用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |